Reckitt’s Revenues Soar On Strength Of Adams Brands, Product Innovations
This article was originally published in The Tan Sheet
Executive Summary
Reckitt-Benckiser's revenues soared 13 percent in fiscal 2008 as health care and personal product sales grew more than twice as fast as its other segments - a trend the firm expects to continue despite private label competition and the global economic slump
You may also be interested in...
NACDS New Products In Brief
Reckitt doubles down with Mucinex
Amid Growth, Reckitt To Launch Mucinex In Emerging Markets Ahead of EU
Emerging markets, the key driver for Reckitt Benckiser's nearly 20% net income growth, will be crucial in the firm's launch of Mucinex decongestants outside the U.S.
Reckitt Sees End Of Mucinex Exclusivity Despite Delay Attempts
Reckitt Benckiser expects to lose OTC exclusivity for its Mucinex cough cold line as early as 2011 even as it attempts to delay private label competition